The insider sales are small and likely liquidity-driven after option exercises. Monitor for any material news (pipeline updates, regulatory filings) that could explain the timing, but no immediate trading action is warranted.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 11 $38.02entry
- T+1 · 2mo ago +2.21%α +2.66% · $38.86
- T+5 · 2mo ago −4.34%α −4.12% · $36.37
- T+20 · 6w ago −18.20%α −20.07% · $31.10
- T+46 · todayOpen
- T+60 · in 20d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Pharvaris insiders, including President Lu Peng, sold a combined $911K in open-market sales this week. The sales follow derivative exercises and are modest relative to the $2.6B market cap (~0.04%), making them routine in scale. No bearish signal is warranted given the small proportionality and the company's strong analyst consensus (90% bullish).
Key Financial Metrics
Key Facts
- President Lu Peng sold 15,000 shares at $40.68 for $610K on 2026-09-08
- Director Robert Glassman sold 8,000 shares at $37.55 for $300K on 2026-09-09
- Both sales followed derivative exercises (non-cash events), Lu exercised options at $2.59, Glassman exercised at $20 and $0
- Total open-market sales of $911K represent ~0.04% of PHVS's $2.6B market cap
- No open-market purchases were made by any insider in the cluster
Financial Impact
Total insider sales of $911K, or ~0.04% of market cap, trivial relative to company size
Risk Factors
- Insider sales, while small, could precede negative news if they accelerate in size or involve C-suite executives selling larger positions
- Biotech stock volatility around clinical data readouts could amplify any future insider activity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PHVS-1789143949683 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers